News
SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target
- SOT109 will leverage antibodies generated with Biocytogen’s proprietary RenMabTM platform as backbone of ADC for colorectal cancer and other gastrointestinal cancers;
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the licensing of fully human antibodies from Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics. The license will be used to develop an innovative antibody drug conjugate (ADC) for a novel tumor target under the option and license agreement established between the companies. The antibody selected will support the development of SOT109, SOTIO’s new ADC candidate, for the treatment of colorectal cancer and other gastrointestinal (GI) cancers.
SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline
- PPF Group provides funding to advance SOTIO through key clinical milestones
- Proceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial
- Three programs (SOT102, BOXR1030, and SOT201) to advance through phase 1
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023.
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
